Summit Therapeutics Inc.
SMMT
Peringkat dalam Saham
#1699
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$15.80
Kapitalisasi Pasar
$12.61B
Perubahan (1 hari)
-1.78%
Perubahan (1 tahun)
-15.67%
Negara
US
Perdagangan Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
Pendapatan untuk Summit Therapeutics Inc. (SMMT)
Pendapatan pada Jun 2026 TTM: 0.00
Menurut laporan keuangan terbaru dari Summit Therapeutics Inc., pendapatan saat ini (TTM) adalah 0.00. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar 0.00 penurunan dibandingkan dengan pendapatan pada tahun 2022 yang sebesar $704.30K. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Summit Therapeutics Inc. dari 2004 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $704.30K | -61.07% |
| 2021 | $1.81M | 110.35% |
| 2020 | $860.00K | 5.99% |
| 2019 | $811.40K | -96.73% |
| 2018 | $24.84M | 585.22% |
| 2017 | $3.63M | 98.76% |
| 2016 | $1.82M | -46.59% |
| 2015 | $3.42M | -8.39% |
| 2014 | $3.73M | -17.91% |
| 2013 | $4.54M | 3.93% |
| 2012 | $4.37M | 126.58% |
| 2011 | $1.93M | 297.91% |
| 2010 | $484.72K | 26.56% |
| 2009 | $383.00K | -96.80% |
| 2008 | $11.98M | 201.54% |
| 2007 | $3.97M | 135.85% |
| 2006 | $1.68M | 320.18% |
| 2005 | $400.93K | 11,995.06% |
| 2004 | $3.31K | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
